Pay in 4 interest-free payments of $5.71 Learn more
Ships within 48 hours · Estimated delivery Oct 7 - Oct 12
CagriSema's Advantages: First to Market: 6-12 month head start Leverages Wegovy Success: Built-in brand recognition Proven Semaglutide Component: Half the drug is already approved Strong Diabetes Data: Positions for dual indication No Dysesthesia: Cleaner safety profile in one key area Retatrutide's Advantages: Higher Efficacy: 28.7% vs 20.4% (8.3 points more) Superior BP Reduction: -14 mmHg vs likely similar to semaglutide Single Molecule: Potentially easier manufacturing Multiple Indications: OA, OSA, obesity, diabetes trials Novel Class: First triple agonist = strong IP protection The Verdict: Market Will Support Both These medications won't compete head-to-head
When demand exceeds evidence, an unregulated marketplace frequently fills the gap
Cancel anytime
Rarely, bicarbonate loss may approach 10 mEq/L
Elevated homocysteine is a modifiable risk factor that can often be reduced through appropriate nutritional and lifestyle interventions
US$ 21.87
US$ 27.48
US$ 24.46
US$ 25.85
US$ 27.97
US$ 20.24
US$ 24.16
US$ 29.66
US$ 28.36
